SSI after infliximab within 4 weeks of colorectal surgery

What is known

• In 60 of 389 Crohn's ileocolonic-resection patients, infliximab within 3 months was associated with 30-day sepsis, intra-abdominal abscess, and readmission on multivariate analysis; a diverting stoma lowered sepsis risk. ¹
• Other cohorts found no significant difference in postoperative infection/complication rates between infliximab and non-infliximab groups, so the association is not consistent across studies. ²

What is unknown / caveats

• One cohort links preop infliximab to sepsis/abscess ¹; another finds no significant difference in infection rates ²
• No excerpt reports a 4-week infliximab window or a discrete SSI incidence figure
• Available data are Crohn's ileocolonic resection, not elective colorectal surgery broadly
• All sources are retrospective cohorts
• The specific SSI rate for a 4-week preoperative infliximab exposure is not established in the retrieved excerpts.

References

1. [No authors listed]. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg. 2008;12(10):1738-44. PMID: 18709420.

2. [No authors listed]. Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?. Colorectal Dis. 2011;13(11):1294-8. PMID: 20969715.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.